Request your kit


You can choose between two options.

Direct ordering the test to be performed in a laboratory or medical unit

Purchase

Pack to send a sample of a dry urine filter for analysis by our teams.

Purchase

Health Problem


Bladder Cancer

  • 2nd most frequent malignancy of the urinary tract
  • 151,189 new cases/year in Europe
  • 145,000 deaths annually worldwide
  • 50-70% recurrence rate

Consequences:

  • Intensive follow-up is required for a period of 5 years.
  • Cystoscopy is the conventional method:
  • High discomfort for patients
  • Costly for the health care: Current bladder cancer surveillance cost: $2.6-3.7B/year
  • Type of cancer with the Most expensive follow-up per-patient from diagnosis to death (169,000$/patient)

Solution

A Reliable and Convenient (non-invasive) solution, based on a urine test for a new and patented biomarker highlysensitive and SPECIFIC in detecting recurrence of bladder cancer, capable of providing adjunct to cystoscopy or reducing the frequency of follow-up, with its associated discomfort for patients, thus improving their quality of life, besides reducing the economic impact of extensive surveillance.

Bladder Cancer

  • 2nd most frequent malignancy of the urinary tract
  • 151,189 new cases/year in Europe
  • 145,000 deaths annually worldwide
  • 50-70% recurrence rate

CONSEQUENCES

  • Intensive follow-up is required for a period of 5 years.
  • Cystoscopy is the conventional method:
  • High discomfort for patients
  • Costly for the health care: Current bladder cancer surveillance cost: $2.6-3.7B/year
  • Type of cancer with the Most expensive follow-up per-patient from diagnosis to death (169,000$/patient)

Reliable and convenient

Highly sensitive and SPECIFIC method in detecting recurrence of bladder cancer capable of providing adjuct to cystoscopy or reducing the frequency of follow-up cystoscopy with its associated discomfort for patients.

Better follow-up

Cystoscopy is the gold standard. Intensive follow-up is required for a period of  5 years with high discomfort for patients and costly for the healthcare.

Non-invasive

Our proprietary and ultrasensitive biomarker for bladder cancer offers the ability to test urine by a non-invasive sample, and it is a more convenient & cost-saving solution for monitoring bladder cancer.

Patients or Individuals at risk

For persons at risk or any patients diagnosed with bladder cancer, this is a more convenient recurrence surveillance method.

Urologists

With an easy and affordable method that deliver reliable results to complement cystoscopy surveillance.

Buy now

UROMONITOR Features

The technology relies on a non-invasive, urine based, molecular test for ultrasensitive detection of bladder cancer biomarker as a complement to cystoscopy follow-up.

Ultrasensitive

Proprietary

Non-invasive

Clinically validated